Vincent Nadeau
Principal BSquared Capital
Vincent Nadeau is Principal at BSQUARED Capital, a new fund built by biotech operators with broad interests in pain and hypersensitivity disorders. Vincent sources investment opportunities, leads company due diligence, and supports new investment decisions and portfolio company relationships.
Previously, Vincent led external pipeline expansion and supported M&A and licensing activities in the BD team at Bellus Health before its acquisition by GSK in June 2023. He also worked as a life sciences consultant, advising biotech companies on drug R&D, competitive positioning, and capital markets strategy.
Vincent holds a PhD in Biochemistry from the University of Toronto and a BSc in Biochemistry from McGill University.
Seminars
Wednesday 27th January 2027
Panel Discussion: Where Are Investors Placing Their Bets Across Pain Therapeutics?
10:00 am
- Which pain targets, technologies and therapeutic approaches are attracting the greatest investment interest today?
- What data package is required to move a program from scientific promise to an investable opportunity?
- How are investors assessing technical, clinical and commercial risk in an increasingly competitive pain landscape?
- Where do investors see the biggest opportunities and unmet needs shaping the next wave of pain innovation?
